Shenzhen Dartmon Biotechnology

Shenzhen Dartmon Biotechnology is a clinical-stage biotechnology company headquartered in Shenzhen, China, specializing in the development of mRNA-based vaccines and therapeutics. The company has established a proprietary technology platform that integrates mRNA sequence design, chemical modification, and lipid nanoparticle (LNP) delivery systems. Its primary research and development efforts are focused on infectious diseases and oncology, with a lead program targeting COVID-19. Dartmon is also advancing candidates for respiratory syncytial virus (RSV) and various solid tumors. Founded in 2021, the company has quickly gained recognition in the Chinese biotech sector, securing significant investment from prominent venture capital firms like Sequoia China and Miracle Plus. Dartmon aims to provide innovative and scalable genomic medicine solutions to address global unmet medical needs.